Brighten Optix announced on the 10th that its consolidated revenue for June reached NT$48.68 million, a 4.81% increase compared to the same period last year. The company’s consolidated revenue for the first half of the year totaled NT$368 million, up 3.1% year-on-year, primarily benefiting from strong growth in emerging markets across the Asia-Pacific region and continued strong sales of its three-in-one myopia control kit.

Brighten Optix maintained high revenue levels in the first half, mainly driven by robust sales growth in the newly developed Asia-Pacific markets (including Australia), which surged 16% year-on-year. Additionally, the company’s three-in-one myopia control kit, offering consumers a comprehensive vision care solution throughout the day, gained favor among downstream customers, supporting steady sales growth. Given the higher average price and greater customization of the three-in-one kit compared to orthokeratology lenses (OK lenses), it has contributed positively to both the company’s sales performance and customer loyalty, fueling stable overall business growth.

Recently, Brighten Optix obtained its third OK lens product registration certificate in the Chinese market, marking the company’s first self-manufactured and self-marketed OK lens product in China. The company plans to complete product launch preparations by the end of this year and officially enter the Chinese OK lens market with its own domestic brand. Considering that domestically produced OK lenses currently account for over 50% of the total Chinese market, Brighten Optix’s Hangzhou-made OK lenses, along with its previously launched Hiline and myOK brands, will target the high-, mid-, and low-end myopia control segments in China, aiming to capture greater market share and influence.

On June 4th, Brighten Optix announced it had officially signed a share exchange agreement with Carl Zeiss Vision International GmbH (hereafter “Carl Zeiss Germany”), a wholly owned subsidiary of the global optical and optoelectronic leader Carl Zeiss AG. The two parties plan to proceed with a share exchange under the regulations of the Business Mergers and Acquisitions Act and related laws.

Brighten Optix will convene an extraordinary shareholders’ meeting on July 22 to vote on the share exchange plan and the application for delisting and termination of public offering. Upon shareholder approval and regulatory clearance, Brighten Optix will become a wholly owned subsidiary of Carl Zeiss Germany. The transaction is expected to be completed, including delisting procedures, by the first quarter of 2026.

Going forward, Brighten Optix will collaborate with the Carl Zeiss Group to invest in the research, development, and manufacturing of a wide range of vision enhancement products, strengthening the technological advantages and application scope of its optical products, thereby benefiting consumers of all ages both domestically and internationally.

Resource: 亨泰光6月營收4,867萬元、月增4.8％ 受兩題材助力上半年年增3.1%